The US Bankruptcy Court gave an order approving the sale of substantially all the assets of Clarus Therapeutics Holdings, Inc. and Clarus Therapeutics, Inc. on October 26, 2022. The debtors have been authorized to sell their substantially all their assets to Tolmar, Inc. for a consideration of $7.25 million in cash, plus future contingent payments, and assumption of assumed liabilities. The buyer is represented by Steven Kennedy of Faegre Drinker Biddle & Reath LLP as its legal advisor.